BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Agostini F, Masato A, Bubacco L, Bisaglia M. Metformin Repurposing for Parkinson Disease Therapy: Opportunities and Challenges. Int J Mol Sci 2021;23:398. [PMID: 35008822 DOI: 10.3390/ijms23010398] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Dolgacheva LP, Zinchenko VP, Goncharov NV. Molecular and Cellular Interactions in Pathogenesis of Sporadic Parkinson Disease. IJMS 2022;23:13043. [DOI: 10.3390/ijms232113043] [Reference Citation Analysis]
2 Newby D, Linden AB, Fernandes M, Molero Y, Winchester L, Sproviero W, Ghose U, Li QS, Launer LJ, Duijn CMV, Nevado-Holgado AJ. Comparative effect of metformin versus sulfonylureas with dementia and Parkinson's disease risk in US patients over 50 with type 2 diabetes mellitus. BMJ Open Diabetes Res Care 2022;10:e003036. [PMID: 36109050 DOI: 10.1136/bmjdrc-2022-003036] [Reference Citation Analysis]
3 Lin G, Tepe B, Mcgrane G, Tipon RC, Croft G, Panwala L, Hope A, Liang AJ, Zuo Z, Wang L, Bellen HJ. Exploring therapeutic strategies for Infantile Neuronal Axonal Dystrophy (INAD/PARK14).. [DOI: 10.1101/2022.08.16.504080] [Reference Citation Analysis]
4 Mendonça IP, de Paiva IHR, Duarte-Silva EP, de Melo MG, da Silva RS, do Nascimento MIX, Peixoto CA. Metformin improves depressive-like behavior in experimental Parkinson's disease by inducing autophagy in the substantia nigra and hippocampus. Inflammopharmacology 2022. [PMID: 35931897 DOI: 10.1007/s10787-022-01043-6] [Reference Citation Analysis]
5 Xu J, Ao Y, Huang C, Song X, Zhang G, Cui W, Wang Y, Zhang X, Zhang Z. Harmol promotes α-synuclein degradation and improves motor impairment in Parkinson’s models via regulating autophagy-lysosome pathway. npj Parkinsons Dis 2022;8:100. [DOI: 10.1038/s41531-022-00361-4] [Reference Citation Analysis]
6 Sanchez-Mirasierra I, Ghimire S, Hernandez-Diaz S, Soukup SF. Targeting Macroautophagy as a Therapeutic Opportunity to Treat Parkinson's Disease. Front Cell Dev Biol 2022;10:921314. [PMID: 35874822 DOI: 10.3389/fcell.2022.921314] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Wu H, Huang D, Zhou H, Sima X, Wu Z, Sun Y, Wang L, Ruan Y, Wu Q, Wu F, She T, Chu Y, Huang Q, Ning Z, Zhang H. Metformin: A promising drug for human cancers. Oncol Lett 2022;24:204. [PMID: 35720480 DOI: 10.3892/ol.2022.13325] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Yu M, Zheng X, Cheng F, Shao B, Zhuge Q, Jin K. Metformin, Rapamycin, or Nicotinamide Mononucleotide Pretreatment Attenuate Cognitive Impairment After Cerebral Hypoperfusion by Inhibiting Microglial Phagocytosis. Front Neurol 2022;13:903565. [DOI: 10.3389/fneur.2022.903565] [Reference Citation Analysis]
9 Rhee EJ. Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone? Endocrinol Metab (Seoul) 2022;37:415-29. [PMID: 35798548 DOI: 10.3803/EnM.2022.304] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Antoniciello F, Roncarati D, Zannoni A, Chiti E, Scarlato V, Chiappori F. Targeting the Essential Transcription Factor HP1043 of Helicobacter pylori: A Drug Repositioning Study. Front Mol Biosci 2022;9:887564. [DOI: 10.3389/fmolb.2022.887564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Outhoff K. Is metformin an anti-aging drug? South African General Practitioner 2022;3:39-40. [DOI: 10.36303/sagp.2022.3.2.0119] [Reference Citation Analysis]
12 Schmidt S, Vogt Weisenhorn DM, Wurst W. Chapter 5 – “Parkinson's disease – A role of non-enzymatic posttranslational modifications in disease onset and progression?”. Molecular Aspects of Medicine 2022. [DOI: 10.1016/j.mam.2022.101096] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]